Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients - Takeaways - MDSpire

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • By

  • Yasuo Imanishi

  • Takumi Imai

  • Hisako Fujii

  • Rei Aida

  • Yuki Nagata

  • Tetsuo Shoji

  • Shinichiro Kashiwagi

  • Tsutomu Takashima

  • Masanori Emoto

  • January 15, 2025

  • 0 min

Share

  • 1

    Aromatase inhibitors increase fracture risk in postmenopausal women with hormone receptor-positive early-stage breast cancer.

  • 2

    Eldecalcitol add-on therapy with risedronate significantly improves lumbar spine, femoral neck, and total hip bone mineral density.

  • 3

    The study enrolled 200 postmenopausal women, with 196 eligible for analysis after excluding those without follow-up BMD data.

  • 4

    The incidence of vertebral fractures was lower in the eldecalcitol group, although not statistically significant.

  • 5

    Eldecalcitol supplementation is a promising strategy to mitigate bone density loss in breast cancer patients undergoing AI treatment.

Original Source(s)

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • by Yasuo Imanishi, Takumi Imai, Hisako Fujii, Rei Aida, Yuki Nagata, Tetsuo Shoji, Shinichiro Kashiwagi, Tsutomu Takashima, Masanori Emoto

  • January 15, 2025

Related Content

Raman spectroscopic fingerprinting uncovers a multi-scale structural–mechanical–transcriptomic coupling landscape in osteoporosis

The endocrine pathway during whole body vibration modulates the immune system and the osteogenesis in postmenopausal women with osteoporosis

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review